Melita Kaltak (born in 1994) works as a scientist at Astherna. She earned her Bachelor’s degree in Biology from the University of Zagreb in Croatia and her Master’s degree in Functional Genomics from the University of Trieste in Italy. Prior to her arrival to the Netherlands, she dedicated two years as a researcher at the Sahlgrenska Cancer Center in Gothenburg, Sweden, working on ultrasensitive sequencing applied on γδ T cells. In 2019, she relocated to the Netherlands to pursue her PhD degree, focused on antisense oligonucleotides targeting Stargardt disease type 1. This collaborative project, supported by the prestigious Marie Skłodowska-Curie Actions grant, involved ProQR Therapeutics and Radboud University. Throughout her doctoral studies, she developed antisense oligonucleotides for several common genetic variants associated with Stargardt disease.